HR 2883 · 117th Congress · Health
Stop Stalling Access to Affordable Medications
Bill Progress
✓
Introduced2
Committee3
House Vote4
Senate5
EnactedLatest: Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 31 - 9.(2021-09-29)
Plain Language Summary
[AI summary unavailable — showing source text]
Stop Stalling Access to Affordable Medications This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug. The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.…
Summarized by Claude AI · Non-partisan · For informational purposes only
CBO Cost Estimate
Congressional Budget OfficeEstimated Budgetary Effects of H.R. 2883, the Stop Stalling Access to Affordable Medications Act
Jul 22, 2022As ordered reported by the House Committee on the Judiciary on September 29, 2021
Full CBO report ↗Official non-partisan budget analysis by the Congressional Budget Office